|
Charles is responsible for research informatics and information technologies, biophysical properties research, and computational chemistry. Joining Neurogen in 1993, he’s played a prominent role in the development and implementation of our Accelerated Intelligent Drug Discovery (AIDD) technology, which integrates high speed compound synthesis, high throughput screening and advanced informatics. Charles is the architect of the informatics system used in the AIDD program and is responsible for the integration of computational chemistry and informatics with automation and control of the chemical synthesis and screening robotics. AIDD can generate drug discovery data in as little as a two-week period, which compares to a several month-long cycle in other drug discovery programs at both large and small pharma companies. His research interests include the development of automated and assisted methodologies for pharmacophore recognition and model development, as well as molecular level interactions key to drug receptor molecular recognition and the conveyance of drug-like properties. Prior to joining Neurogen, Charles held positions of increasing responsibility in chemistry at Eli Lilly and Dow Elanco. Charles holds a B.S. degree in chemistry from the University of North Carolina, Greensboro, and a Ph.D in chemistry from Harvard University in Massachusetts.
| 